Floatz logo

Nbp

Cognitive Impairment

Pennington Biomedical Research CenterN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Rivastigmine
VA Office of Research and Development
Phase 4BB
Namenda
UNC Lineberger Comprehensive Cancer Center
Phase 3BB
Egb 761®
Ipsen
Phase 4BB
Pioglitazone
University of Colorado, Denver
Phase 4BB
Choline Alfoscerate
Chong Kun Dang Pharmaceutical
Phase 4BB

View all 50 →

Same molecule, other indications

Nbp is also rated in:

anterior cerebral artery infarctionDormant
BB
Indicative ·
67 / 100
View asset →
AISDormant
B
Indicative ·
57 / 100
View asset →
peripheral neuropathyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →